FFilingSight

DexCom Inc. (DXCM) 10-K Red Flags

Risk signals extracted deterministically from DexCom Inc.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.

Detected red flags (10)

  • Gross margin compression: Gross margin contracted +616.9%pp (from 2586.7% to 1969.8%). This may reflect input cost inflation, pricing pressure, or product mix shift toward lower-margin segments.
  • Operating cash flow exceeds net income: OCF is 1.38x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • R&D intensity declining: R&D as % of revenue fell from 665.1% to 435.3%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
  • Endogenous analysis: 1 positive signal(s) versus 1 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
  • 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • Market cap $27.49B at $71.25 per share.
  • Trailing P/E 54.81, P/S 236.60, P/B 9.30.
  • Composite risk: Moderate.
  • Leverage debt/equity 0.00 (low).

Filings & ownership

  • Latest annual report (10-K) filed Feb 12, 2026.
  • Latest quarterly report (10-Q) filed Apr 30, 2026.
  • 13 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference DexCom Inc.; broad institutional reporting.
  • Recent filers include PURA VIDA INVESTMENTS, LLC, Rothschild Capital Partners, LLC, WS MANAGEMENT LLLP.

Full DXCM analyst report

Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.

View full report →

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.